Nutriband (NASDAQ:NTRB) Stock Rating Lowered by Zacks Research

Key Points

• Nutriband has been downgraded by Zacks Research from a "hold" rating to a "strong sell" rating, signaling concerns about the company's current performance.
• The company reported an earnings per share (EPS) loss of ($2.12) for the quarter, significantly missing analysts' expectations and revealing a negative net margin of 398.29%.
• An institutional investor, US Bancorp DE, recently purchased shares, acquiring 4,798 shares valued at approximately $29,000, indicating some institutional interest despite the downgrade.

Zacks Research lowered shares of Nutriband (NASDAQ:NTRB - Free Report) from a hold rating to a strong sell rating in a report published on Tuesday morning,Zacks.com reports.

Nutriband Price Performance

Shares of NASDAQ NTRB traded up $0.07 during trading on Tuesday, reaching $7.29. The company had a trading volume of 24,024 shares, compared to its average volume of 33,094. Nutriband has a 52 week low of $3.72 and a 52 week high of $11.78. The stock has a market cap of $87.70 million, a PE ratio of -2.54 and a beta of 1.13. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.70 and a current ratio of 4.78. The business's 50 day moving average price is $7.02 and its 200-day moving average price is $6.71.

Nutriband (NASDAQ:NTRB - Get Free Report) last announced its earnings results on Tuesday, September 9th. The company reported ($2.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($1.95). Nutriband had a negative return on equity of 85.40% and a negative net margin of 398.29%.The company had revenue of $0.62 million during the quarter, compared to the consensus estimate of $0.71 million. Analysts expect that Nutriband will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On Nutriband

An institutional investor recently bought a new position in Nutriband stock. US Bancorp DE purchased a new position in shares of Nutriband Inc. (NASDAQ:NTRB - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 4,798 shares of the company's stock, valued at approximately $29,000. Hedge funds and other institutional investors own 19.70% of the company's stock.

Nutriband Company Profile

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.